Shanghai Ruiliyuan Biotechnology Co., Ltd.

This is an early-stage safety study testing a new type of immune cell therapy called HRYZ-T102. It is for adults with advanced liver cancer or other solid tumors that have stopped responding to standard treatments and who have a specific genetic marker (HLA-A 02:03). Researchers …